Penserra Capital Management LLC Nektar Therapeutics Transaction History

Penserra Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$10.83 - $18.41 $45,540 - $77,414	-4,205 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $718 - $1,036	55 Added 1.33%	4,205 $75,000
Q2 2021 Aug 12, 2021	BUY	$16.52 - $20.4 $495 - $612	30 Added 0.73%	4,150 $71,000
Q1 2021 May 13, 2021	SELL	$16.56 - $25.46 $413 - $636	-25 Reduced 0.6%	4,120 $82,000
Q4 2020 Feb 12, 2021	BUY	$15.77 - $19.03 $41,270 - $49,801	2,617 Added 171.27%	4,145 $70,000
Q3 2020 Nov 13, 2020	BUY	$16.59 - $24.79 $25,349 - $37,879	1,528 New	1,528 $25,000
Q4 2018 Feb 06, 2019	SELL	$30.43 - $56.65 $25,682 - $47,812	-844 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$46.46 - $68.49 $1.06 Million - $1.56 Million	-22,787 Reduced 96.43%	844 $51,000
Q2 2018 Aug 13, 2018	BUY	$46.25 - $104.45 $1.09 Million - $2.47 Million	23,631 New	23,631 $1.15 Million

152

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.